AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: GLORIA LAU
Bacterial resistance to existing drugs is growing, making the need for new antibiotics more urgent. Yet drug companies show little interest in developing new antibiotics.
One reason drug makers aren't focusing on antibiotics is the high cost to develop them, says Dr. John Edwards Jr., chief of infectious diseases at Harbor/UCLA Medical Center in Los Angeles.
Antibiotics also have a short market life, he says. They can generate only days or weeks of sales and profit for drug makers. In contrast, drugs that are taken by patients for chronic conditions bring in far more revenue and profit.
Edwards and his colleagues co-authored a study on the antibiotics market for a recent issue of the journal Clinical Infectious Diseases. Edwards recently spoke with IBD.
IBD: Why are so few drug makers willing to fund research and development of new antibiotics?
Edwards: Antibiotics define their own life span compared to drugs that are used for the treatment of hypertension or drugs that lower cholesterol and lipids.